280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA
Transform Therapies. Reimagine Lives. Phase 2b Topline Results September 1, 2026
Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements
Long-term Data Positioned to Set a New Standard for Plaque Psoriasis Treatment, Delivering Highest Reported PASI 100 Skin Clearance Among Oral Therapies
Election of Directors at Alumis Inc. Annual Meeting - James Tananbaum Elected
Investor Presentation
Annual Report to Security Holders
Reports First Quarter 2026 Financial Results and Highlights Recent Achievements
Q2
Q1
FY 2025
Q3
Amended Annual Report
FY 2024
S-3ASR
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus Filed Pursuant to Rule 425
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Schedule 13D - Ownership Report
Schedule 13G - Ownership Report